Total submissions: 5
Submitter | RCV | SCV | Clinical significance | Condition | Last evaluated | Review status | Method | Comment |
---|---|---|---|---|---|---|---|---|
Labcorp Genetics |
RCV000204633 | SCV000259801 | pathogenic | Fanconi anemia | 2023-08-18 | criteria provided, single submitter | clinical testing | This variant disrupts a region of the FANCA protein in which other variant(s) (p.Asp1427Thrfs*6) have been determined to be pathogenic (PMID: 11091222). This suggests that this is a clinically significant region of the protein, and that variants that disrupt it are likely to be disease-causing. For these reasons, this variant has been classified as Pathogenic. ClinVar contains an entry for this variant (Variation ID: 219753). This premature translational stop signal has been observed in individual(s) with Fanconi anemia (PMID: 9371798). This variant is present in population databases (rs747892390, gnomAD 0.002%). This sequence change creates a premature translational stop signal (p.Ala1357Leufs*63) in the FANCA gene. While this is not anticipated to result in nonsense mediated decay, it is expected to disrupt the last 99 amino acid(s) of the FANCA protein. |
Counsyl | RCV000668440 | SCV000793045 | pathogenic | Fanconi anemia complementation group A | 2017-07-26 | criteria provided, single submitter | clinical testing | |
Baylor Genetics | RCV000668440 | SCV004195989 | pathogenic | Fanconi anemia complementation group A | 2024-03-10 | criteria provided, single submitter | clinical testing | |
Mayo Clinic Laboratories, |
RCV003480552 | SCV004226798 | pathogenic | not provided | 2023-04-28 | criteria provided, single submitter | clinical testing | PM2, PM3_supporting, PVS1 |
Leiden Open Variation Database | RCV000668440 | SCV001425733 | pathogenic | Fanconi anemia complementation group A | 2020-02-28 | no assertion criteria provided | curation | Curator: Arleen D. Auerbach. Submitters to LOVD: Arleen D. Auerbach, Johan de Winter. |